Comparison · NCT00600756-9be69fef
Quetiapine XR vs Risperidone: The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Number of Participants Who Had at Least 1 Extra-pyramidal TEAE at Month 12 in the Safety Population
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Quetiapine XR vs Risperidone: The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Number of Participants Who Had at Least 1 Extra-pyramidal TEAE at Month 12 in the Safety Population. Trial comparisons, record NCT00600756-9be69fef. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00600756-9be69fef
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0972 | 0.0716 | 0.131 | wilson | |
| Risk in group 2 | 0.206 | 0.17 | 0.249 | wilson | |
| Risk difference, group 1 minus group 2 | -0.109 | -0.159 | -0.0597 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.471 | 0.329 | 0.673 | log | |
| Odds ratio, group 1 over group 2 | 0.414 | 0.274 | 0.625 | log | |
| Number needed to treat, for one fewer participant with the outcome on Quetiapine XR than on Risperidone | 9.15 | 6.3 | 16.8 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Quetiapine XR | Experimental - oral, once daily, tablets of 400 mg to 800 mg | 38 | 391 | OG000 |
| Group 2 | Risperidone | Active Comparator - oral, once daily, tablets of 2 mg to 6 mg | 83 | 402 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Number of Participants Who Had at Least 1 Extra-pyramidal TEAE at Month 12 in the Safety Population
- Description
- Treatment-emergent adverse events are defined as adverse events that occurred after the first intake of the study medication (or on the same day).
- Time frame
- 12 months
- Population
The Safety population at Month 12 is presented. For Quetiapine XR, 4 subjects did not take study drug, resulting in 391 evaluable subjects compared with the Randomized population (395 subjects). For Risperidone, 1 subject did not take study drug, results in 402 evaluable subjects compared with the Randomized population (403 subjects).
Source ClinicalTrials.gov
Trial
- Title
- Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone
- NCT number
- NCT00600756
- Phases
- PHASE3
- Conditions
- Schizophrenic Disorders
- Interventions
- Quetiapine XR, Risperidone
- Lead sponsor
- AstraZeneca
- Results first posted
- 2012-09-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00600756?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00600756-9be69fef